Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Plain-language summary
This trial is testing Adebrelimab & SHR2554 for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Adebrelimab & SHR2554 (DRUG): ①Phase Ib : SHR2554 350 mg twice daily ; Adebrelimab 1200 mg, IV infusion for 1 cycle(21days) ②Phase II ：Adebrelimab RP2D (600 mg or 1200 mg ), IV infusion ,D1 Q3W ; SHR2554 : 350 mg，twice daily ; Up to 6 cycles. ③Maintenance therapy : SHR2554 350 mg，twice daily (28 days per cycle) ,not exceed 24 months.
Adebrelimab & SHR2554
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details